Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 25Neoplasms 3Neoplasm Metastasis 3Stomach Neoplasms 1Sarcoma 1Osteitis Deformans 1Neoplastic Cells, Circulating 1Invasive Breast Cancer 1Head and Neck Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER2 Positive Metastatic Breast Cancer 1Esophageal Neoplasms 1Carcinoma 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Cisplatin 31Fluorouracil 24Paclitaxel 19Radiotherapy 15Docetaxel 11Esophagectomy 8Radiation 7Neoadjuvant Therapy 7Carboplatin 7Irinotecan 6Oxaliplatin 5Leucovorin 5Capecitabine 5sintilimab 4pembrolizumab 4camrelizumab 4TP protocol 4Surgical Procedures, Operative 4Drug Therapy 4Chemotherapy, Adjuvant 4Trastuzumab 3Immunotherapy 3Epirubicin 3Chemoradiotherapy 3tislelizumab 2nimotuzumab 2S 1 (combination) 2Radiotherapy, Adjuvant 2Platinum Compounds 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Neoplasms × Lapatinib × Clear all
NCT00680901 2025-08-07

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Novartis

Phase 3 Completed
545 enrolled 24 charts
Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡